Irlvixro Wart Remover for Common Plantar Warts

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of common and plantar warts.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. For optimal results, it is recommended to soak the wart in warm water for approximately 5 minutes. After soaking, the area must be dried thoroughly to ensure proper adhesion of the treatment.

Using the provided applicator, one drop of the medication should be applied at a time to sufficiently cover each wart. It is important to allow the application to dry completely before proceeding. This procedure may be repeated once or twice daily as needed, continuing until the wart is removed.

The duration of treatment may extend up to 12 weeks, depending on the individual response and the persistence of the wart.

Contraindications

Use is contraindicated in the following situations:

Application on moles, birthmarks, or warts with hair growth is prohibited due to the potential for adverse effects. Additionally, the product should not be applied to irritated skin or any area that is infected or reddened, as this may exacerbate the condition. Furthermore, individuals with diabetes or poor blood circulation should avoid use, as these conditions may increase the risk of complications.

Warnings and Precautions

For external use only. This product is not intended for internal application.

General precautions must be observed to ensure safe use. It is contraindicated to apply this product on moles, birthmarks, or warts that have hair growing from them. Additionally, it should not be used on irritated skin or any area that appears infected or reddened. Patients with diabetes or poor blood circulation should refrain from using this product due to the increased risk of adverse effects.

In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Users are advised to discontinue use and consult a healthcare professional if discomfort persists or if excessive irritation occurs. Monitoring for these symptoms is essential to prevent potential complications.

Side Effects

Patients using this product should be aware that it is intended for external use only. In the event that discomfort persists or excessive irritation occurs, it is advised to discontinue use and consult a healthcare professional.

While specific adverse reactions have not been detailed in clinical trials or postmarketing experiences, the potential for discomfort and irritation is noted. Participants should monitor their response to the product and seek medical advice if they experience ongoing issues.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Irlvixro Wart Remover for Common Plantar Warts (wart remover for common plantar warts). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep the medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

The available prescribing information does not provide specific data regarding the use of this product during pregnancy. There are no contraindications noted for use in pregnant patients, nor are there any associated risks to the fetus identified in the available literature. Additionally, no dosage modifications or special precautions for use during pregnancy are mentioned. Healthcare professionals should consider the lack of data when prescribing this product to women of childbearing potential and weigh the potential benefits against any unknown risks.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. Further research may be necessary to fully understand the implications for breastfed infants.

Renal Impairment

Patients with renal impairment may necessitate a reduced dose of the medication. It is essential for healthcare professionals to assess creatinine clearance prior to initiating therapy in these patients. Regular renal function tests are recommended for individuals with existing kidney problems to monitor their condition effectively. Additionally, special monitoring is required for patients with significant renal impairment to avoid potential toxicity associated with the medication.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the clinical presentation of an overdose may vary depending on the substance involved and the individual patient’s characteristics. Symptoms of overdose can range from mild to severe and may include altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical evaluation is recommended. Healthcare professionals should assess the patient's vital signs and conduct a thorough clinical examination. Supportive care should be initiated as necessary, which may include airway management, intravenous fluids, and monitoring of vital parameters.

If specific antidotes or treatments are available for the substance involved, they should be administered according to established protocols. Consultation with a poison control center or toxicology expert may also be warranted to guide management decisions.

It is crucial to document all findings and interventions in the patient's medical record and to report any adverse events to the appropriate regulatory authorities as required.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's safety profile in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to instruct patients not to apply the product on moles, birthmarks, or warts that have hair growing from them, as well as to avoid using it on irritated skin or any area that appears infected or reddened.

Patients should be informed that the product is not suitable for individuals with diabetes or poor blood circulation. They should be counseled to discontinue use if discomfort persists or if excessive irritation occurs.

Additionally, healthcare providers should emphasize the importance of avoiding contact with the eyes during application. In the event that the product does come into contact with the eyes, patients should be instructed to flush the eyes with water for 15 minutes and seek medical attention if irritation continues.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at a temperature range of 20–25°C (68–77°F) and protected from freezing. Additionally, it is important to avoid exposure to excessive heat or flame to ensure the product remains safe and effective.

Additional Clinical Information

The product is administered topically, with the recommended frequency being once or twice daily as needed until the wart is removed. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Irlvixro Wart Remover for Common Plantar Warts, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)